PT - JOURNAL ARTICLE AU - Graham, Mark S. AU - May, Anna AU - Varsavsky, Thomas AU - Sudre, Carole H. AU - Murray, Benjamin AU - Kläser, Kerstin AU - Antonelli, Michela AU - Canas, Liane S. AU - Molteni, Erika AU - Modat, Marc AU - Cardoso, M. Jorge AU - Drew, David A. AU - Nguyen, Long H. AU - Rader, Benjamin AU - Hu, Christina AU - Capdevila, Joan AU - Hammers, Alexander AU - Chan, Andrew T. AU - Wolf, Jonathan AU - Brownstein, John S. AU - Spector, Tim D. AU - Ourselin, Sebastien AU - Steves, Claire J. AU - Astley, Christina M. TI - Knowledge barriers in the symptomatic-COVID-19 testing programme in the UK: an observational study AID - 10.1101/2021.03.16.21253719 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.16.21253719 4099 - http://medrxiv.org/content/early/2021/03/18/2021.03.16.21253719.short 4100 - http://medrxiv.org/content/early/2021/03/18/2021.03.16.21253719.full AB - Background Symptomatic testing programmes are crucial to the COVID-19 pandemic response. We sought to examine United Kingdom (UK) testing rates amongst individuals with test-qualifying symptoms, and factors associated with not testing.Methods We analysed a cohort of untested symptomatic app users (N=1,237), nested in the Zoe COVID Symptom Study (Zoe, N= 4,394,948); and symptomatic survey respondents who wanted, but did not have a test (N=1,956), drawn from the University of Maryland-Facebook Covid-19 Symptom Survey (UMD-Facebook, N=775,746).Findings The proportion tested among individuals with incident test-qualifying symptoms rose from ∼20% to ∼75% from April to December 2020 in Zoe. Testing was lower with one vs more symptoms (73.0% vs 85.0%), or short vs long symptom duration (72.6% vs 87.8%). 40.4% of survey respondents did not identify all three test-qualifying symptoms. Symptom identification decreased for every decade older (OR=0.908 [95% CI 0.883-0.933]). Amongst symptomatic UMD-Facebook respondents who wanted but did not have a test, not knowing where to go was the most cited factor (32.4%); this increased for each decade older (OR=1.207 [1.129-1.292]) and for every 4-years fewer in education (OR=0.685 [0.599-0.783]).Interpretation Despite current UK messaging on COVID-19 testing, there is a knowledge gap about when and where to test, and this may be contributing to the ∼25% testing gap. Risk factors, including older age and less education, highlight potential opportunities to tailor public health messages.Funding Zoe Global Limited, Department of Health, Wellcome Trust, EPSRC, NIHR, MRC, Alzheimer’s Society, Facebook Sponsored Research Agreement.Evidence before this study To assess current evidence on test uptake in symptomatic testing programmes, and the reasons for not testing, we searched PubMed from database inception for research using the keywords (COVID-19) AND (testing) AND ((access) OR (uptake)). We did not find any work reporting on levels of test uptake amongst symptomatic individuals. We found three papers investigating geographic barriers to testing. We found one US based survey reporting on knowledge barriers to testing, and one UK based survey reporting on barriers in the period March - August 2020. Neither of these studies were able to combine testing behaviour with prospectively collected symptom reports from the users surveyed.Added value of this study Through prospective collection of symptom and test reports, we were able to estimate testing uptake amongst individuals with test-qualifying symptoms in the UK. Our results indicate that whilst testing has improved since the start of the pandemic, there remains a considerable testing gap. Investigating this gap we find that individuals with just one test-qualifying symptom or short symptom duration are less likely to get tested. We also find knowledge barriers to testing: a substantial proportion of individuals do not know which symptoms qualify them for a COVID-19 test, and do not know where to seek testing. We find a larger knowledge gap in individuals with older age and fewer years of education.Implications of all the available evidence Despite the UK having a simple set of symptom-based testing criteria, with tests made freely available through nationalised healthcare, a quarter of individuals with qualifying symptoms do not get tested. Our findings suggest testing uptake may be limited by individuals not acting on mild or transient symptoms, not recognising the testing criteria, and not knowing where to get tested. Improved messaging may help address this testing gap, with opportunities to target individuals of older age or fewer years of education. Messaging may prove even more valuable in countries with more fragmented testing infrastructure or more nuanced testing criteria, where knowledge barriers are likely to be greater.Competing Interest StatementThe authors CMA, BR and JSB declare no competing interests. AM, JCP, CH, JW are employees of Zoe Global Ltd. TDS is a consultant to Zoe Global Ltd. DAD and ATC previously served as investigators on a clinical trial of diet and lifestyle using a separate smartphone application that was supported by Zoe Global. ATC reports grants from Massachusetts Consortium on Pathogen Readiness, during the conduct of the study; personal fees from Pfizer Inc., personal fees from Boehringer Ingelheim, personal fees from Bayer Pharma AG, outside the submitted work. DAD reports grants from National Institutes of Health, grants from MassCPR, grants from American Gastroenterological Association during the conduct of the study.Funding StatementCMA and JSB: Facebook Sponsored Research Agreement [INB1116217]. CHS Alzheimer's Society Junior Fellowship [AS-JF-17-011]. Support for the COVID Symptom Study (UK data) was provided by the NIHR-funded Biomedical Research Centre based at GSTT NHS Foundation Trust. This work was supported by the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare. ZOE Global provided in kind support for all aspects of building, running and supporting the app and service to all users worldwide. Support for this study was provided by the NIHR-funded Biomedical Research Centre based at GSTT NHS Foundation Trust. Investigators also received support from the Wellcome Trust (212904/Z/18/Z, WT203148/Z/16/Z), the MRC/BHF (MR/M016560/1), Alzheimer's Society, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL, the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, the Wellcome Flagship Programme (WT213038/Z/18/Z), the Chronic Disease Research Foundation, and DHSC. ATC was supported in this work through a Stuart and Suzanne Steele MGH Research Scholar Award. The Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz supported MGH investigators (DAD, LHN, ATC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Boston Children's Hospital IRB (P00023700) to use UMD-Facebook data. King's College London ethics committee (REMAS ID 18210; LRS-19/20-18210) to use Zoe data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesZoe Platform data used in this study is available to researchers through UK Health Data Research using the following link: https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259 Requests for UMD/Facebook data may be completed through: https://dataforgood.fb.com/docs/covid-19-symptom-survey-request-for-data-access/